EUCTR2017-003229-14-LT进行中（未招募）1 期
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients with Moderately to Severely Active Ulcerative Colitis (LUCENT 1) - LUCENT 1
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Principal Inclusion Criteria are as follows:
- •1. Male or female patients =18 and =80 years of age at the time of initial screening
- •2. Diagnosis of UC for at least 3 months prior to baseline.
- •3. Confirmed diagnosis of moderately or severely active UC, as assessed by the modified Mayo score (MMS).
- •4. Demonstrated an inadequate response to, a loss of response to, or an intolerance to conventional or to biologic therapy for UC.
- •5. If female, must meet the contraception requirements.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 1044
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 116
排除标准
- •Principal Exclusion Criteria are as follows:
- •1. Patients with a current diagnosis of Crohn’s disease or inflammatory bowel disease-unclassified (indeterminate colitis).
- •2. Patients with a previous colectomy.
- •3. Patients with current evidence of toxic megacolon.
- •4. Prior exposure to anti-IL12p40 antibodies (e.g. ustekinumab) or anti-IL-23p19 antibodies (e.g. risankizumab, brazikumab, guselkumab or tildrakizumab).
研究者
相似试验
进行中（未招募）
1 期
Research study of Rolapitant versus Placebo for the prevention of nausea and vomiting related to chemotherapy that has a high likelihood of inducing nausea and vomiting.Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Receiving Highly Emetogenic Chemotherapy (HEC)MedDRA version: 14.1 Level: PT Classification code 10054133 Term: Prophylaxis of nausea and vomiting System Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 14.1 Level: LLT Classification code 10049091 Term: Chemotherapy antiemetic prophylaxis System Organ Class: 10042613 - Surgical and medical proceduresEUCTR2010-022742-25-ESTesaro, Inc.526
进行中（未招募）
不适用
Research study of Rolapitant versus Placebo for the prevention of nausea and vomiting related to chemotherapy that has a high likelihood of inducing nausea and vomiting.Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Receiving Highly Emetogenic Chemotherapy (HEC)MedDRA version: 16.0Level: PTClassification code 10054133Term: Prophylaxis of nausea and vomitingSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 16.0Level: LLTClassification code 10049091Term: Chemotherapy antiemetic prophylaxisSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2010-022742-25-PTTesaro, Inc.530
进行中（未招募）
不适用
AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastricor Esophagogastric Junction CancerEUCTR2011-004923-11-ITAMGEN INC.450
招募中
1 期
A Clinical Trial to Test the Safety, Effect, and Activity of Rilzabrutinib (PRN1008) in Adult and Adolescent Patients with Persistent or Chronic Immune Thrombocytopenia (ITP).CTIS2023-509401-71-00Principia Biopharma Inc.224
进行中（未招募）
不适用
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE) (ILLUMINATE-2) - ILLUMINATE-2Systemic Lupus Erythematosus (SLE)MedDRA version: 14.1Level: LLTClassification code 10025139Term: Lupus erythematosus systemicSystem Organ Class: 100000004859EUCTR2010-022100-42-HUEli Lilly and Company1,140